Item 1.01 Entry into a Material Definitive Agreement On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”). The Company will pay interest on the Notes on June 30 and December 30 of each year, beginning on December 30, 2026. The Notes will mature on June 30, 2036.…
Filed May 8, 2026Accepted May 8, 2026, 4:15 PM EDTCIK 1022079Accession 0001104659-26-057938
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www. QuestDiagnostics.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement
On May 6, 2026, Quest Diagnostics Incorporated (the “Company”)
issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).
The Company will pay interest on the Notes on June 30 and December
30 of each year, beginning on December 30, 2026.
The Notes will mature on June 30, 2036. The Notes will be the senior
unsecured obligations of the Company and will rank equally with the Company’s other existing and future senior unsecured obligations.
The Notes will not be entitled to the benefit of any sinking fund.
The Notes were issued pursuant to an indenture dated as of June 27,
2001 among the Company, the guarantors (as defined therein) and The Bank of New York Mellon, as trustee (the “Trustee”), as
supplemented from time to time, and as further supplemented by a twenty-fourth supplemental indenture dated as of May 6, 2026 between
the Company and the Trustee (collectively, the “Indenture”). The Indenture contains covenants that, among other things, will
limit the ability of (i) the Company and certain of its subsidiaries to create certain liens and enter into certain sale and leaseback
transactions and (ii) the Company to consolidate, merge or transfer all or substantially all of the Company’s assets on a consolidated
basis. The Indenture provides for customary events of default. Upon a change of control triggering event (as defined in the Indenture),
the Company will be required to make an offer to purchase the Notes at a price equal to 101% of their principal amount plus accrued and
unpaid interest to the repurchase date.
The foregoing description of the Indenture does not purport to be complete
and is qualified in its entirety by reference to the text of the applicable agreements, each of which is included as an exhibit to this
Current Report on Form 8-K and incorporated by reference herein.
A copy of the opinion of Allen Overy Shearman Sterling US LLP, counsel
to the Company, relating to the legality of the Notes is filed as Exhibit 5.1 to this Current Report on Form 8-K.
Filed exhibits (1)
EX-4.2 (by filename) tm2613096d2_ex4-2.htm
EX-4.2
2
tm2613096d2_ex4-2.htm
EXHIBIT 4.2
Exhibit 4.2
QUEST DIAGNOSTICS INCORPORATED,
as Issuer
and
THE BANK OF NEW YORK MELLON,
as Trustee
Twenty-Fourth Supplemental Indenture
Dated as of May 6, 2026
TABLE
OF CONTENTS
Page
Article I. DEFINITIONS 3
SECTION 1.1. Certain Terms Defined in the Indenture 3
SECTION 1.2. Definitions 3
SECTION 1.3. Other Definitions 6
Article II. FORM AND TERMS OF THE NOTES 6
SECTION 2.1. Form and Dating …